PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
IPO Year: 2017
Exchange: NASDAQ
Website: petiq.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $30.00 → $31.00 | Buy → Hold | Truist |
| 12/19/2023 | $22.00 | Buy | Jefferies |
| 9/6/2023 | $28.00 | Buy | Lake Street |
| 5/13/2022 | Outperform → Perform | Oppenheimer | |
| 3/3/2022 | $32.00 → $29.00 | Outperform | Raymond James |
| 11/30/2021 | $30.00 | Buy | The Benchmark Company |
| 11/30/2021 | $30.00 | Buy | Benchmark |
| 11/4/2021 | $41.00 → $32.00 | Outperform | Raymond James |
15-12G - PetIQ, Inc. (0001668673) (Filer)
S-8 POS - PetIQ, Inc. (0001668673) (Filer)
S-8 POS - PetIQ, Inc. (0001668673) (Filer)
S-8 POS - PetIQ, Inc. (0001668673) (Filer)
25-NSE - PetIQ, Inc. (0001668673) (Subject)
S-8 POS - PetIQ, Inc. (0001668673) (Filer)
8-K - PetIQ, Inc. (0001668673) (Filer)
8-K - PetIQ, Inc. (0001668673) (Filer)
DEFA14A - PetIQ, Inc. (0001668673) (Filer)
8-K - PetIQ, Inc. (0001668673) (Filer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
4 - PetIQ, Inc. (0001668673) (Issuer)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and co
EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. "On behalf of PetIQ's Board of Directors, we are excited to announce stockholders' approval of our proposed transaction with Bansk Group, repre
Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati
EAGLE, Idaho, and NEW YORK, New York, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, and Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that PetIQ entered into a definitive agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. PetIQ's Board of Directors (the "Board") has approved the Agreement, which represents a premium of approximately 41% to the 30-day
EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live
EAGLE, Idaho, June 05, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today announced that members of its executive management team will participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference. A virtual fireside chat will be available on Tuesday, June 11, 2024 at 10:30 a.m. EDT. The live webcast and replay is accessible on the "Investors" section of the Company's website at www.PetIQ.com. About PetIQ PetIQ is a leading pet medication, health and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to
Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel
EAGLE, Idaho, April 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the first quarter ended March 31, 2024, on Wednesday, May 8, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, May 8, 2024. To participate on the live call listeners in North America may dial 833-816-1410 and international listeners may dial 412-317-0503. In addition, the call will be broadcast live over the Internet ho
EAGLE, Idaho, March 14, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product, and wellness company, has announced the launch of Minties® dental treats for large-sized dogs, expanding the Minties® brand to now include affordable, veterinarian-recommended dental treats for tiny/small, medium, and large-sized dogs, as well as cats. Recommended for dogs over fifty pounds, the Minties® large dental treat includes the tasty, breath-freshening ingredients found in Minties'® other best-selling dental treats for tiny/small (5 to 24 lbs) and medium-sized (25 to 50 lbs) dogs. With five natural breath fresheners – alfalfa, peppermint, pars
EAGLE, Idaho, March 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, has officially kicked off flea & tick season with NextStar,® the fastest-acting 30-day topical protection available,* to help educate pet parents on year-round monthly prevention to get ahead of seasonal upticks in infestations and keep pets and the moments pet parents share with them protected. Available at local retailers and online with no prescription needed, NextStar's® veterinarian-recommended** formula not only kills fleas and ticks; it also kills mosquitoes, chewing lice, flea eggs, flea larvae, and prevents the developme
Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously
Jefferies initiated coverage of PetIQ with a rating of Buy and set a new price target of $22.00
Lake Street initiated coverage of PetIQ with a rating of Buy and set a new price target of $28.00
Oppenheimer downgraded PetIQ from Outperform to Perform
Raymond James reiterated coverage of PetIQ with a rating of Outperform and set a new price target of $29.00 from $32.00 previously
The Benchmark Company initiated coverage of PetIQ with a rating of Buy and set a new price target of $30.00
Benchmark initiated coverage of PetIQ with a rating of Buy and set a new price target of $30.00
Raymond James reiterated coverage of PetIQ with a rating of Outperform and set a new price target of $32.00 from $41.00 previously
Raymond James reiterated coverage of PetIQ with a rating of Outperform and set a new price target of $45.00 from $35.00 previously
Raymond James reiterated coverage of PetIQ with a rating of Outperform and set a new price target of $45.00 from $35.00 previously
Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati
EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live
Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel
EAGLE, Idaho, April 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the first quarter ended March 31, 2024, on Wednesday, May 8, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, May 8, 2024. To participate on the live call listeners in North America may dial 833-816-1410 and international listeners may dial 412-317-0503. In addition, the call will be broadcast live over the Internet ho
Record Full Year 2023 Net Sales Increase 19.6% Year-Over-Year to Over $1.1 BillionAdjusted EBITDA Exceeds Company's Full Year 2023 GuidanceReports Highest Annual Cash from Operations in the Company's History of $61.9 MillionProvides First Quarter 2024 and Full Year 2024 Outlook EAGLE, Idaho, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the fourth quarter and full year ended December 31, 2023. Cord Christensen, PetIQ's Founder and CEO commented, "2023 was a record year for PetIQ. I am very proud of our team's execution to grow our business, enabling u
EAGLE, Idaho, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, on Wednesday, February 28, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, February 28, 2024. To participate on the live call listeners in North America may dial 833-816-1410 and international listeners may dial 412-317-0503. In addition, the call will be broadcast live
Record Third Quarter 2023 Net Sales Increase 32% to $277.0 Million Net Sales and Adjusted EBITDA Exceed Company's Third Quarter 2023 Guidance Highest Year-to-Date Cash from Operations in the Company's History of $64.7 Million Announces Services Segment Optimization Raises 2023 Annual Outlook EAGLE, Idaho, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today reported financial results for the third quarter and nine months ended September 30, 2023. Cord Christensen, PetIQ's Chairman & CEO commented, "We are pleased to report the highest third quarter financial results in the history of the Company.
EAGLE, Idaho, Oct. 17, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 7, 2023, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Tuesday, November 7, 2023. To participate on the live call listeners in North America may dial 833-816-1410 and international listeners may dial 412-317-0503. In addition, the call will be broadcast live over the Internet h
Record Second Quarter 2023 Net Sales Increase 25% to $314.5 Million Net Sales and Adjusted EBITDA Exceeds Company's Second Quarter 2023 Guidance Record Second Quarter Cash from Operations of $57.7 Million Raises 2023 Annual Outlook EAGLE, Idaho, Aug. 08, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today reported financial results for the second quarter and six months ended June 30, 2023. Cord Christensen, PetIQ's Chairman & CEO commented, "We are pleased to continue the year with second-quarter sales and adjusted EBITDA significantly exceeding our guidance. The strategic investments to drive awareness and
EAGLE, Idaho, July 20, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced it will report financial results for the second quarter ended June 30, 2023, on Tuesday, August 8, 2023, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Tuesday, August 8, 2023. To participate on the live call listeners in North America may dial 833-816-1410 and international listeners may dial 412-317-0503. In addition, the call will be broadcast live over the Internet hosted at
EAGLE, Idaho, Aug. 02, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced that John Pearson, who has served as the Company's Senior Vice President, Head of Services since 2022, has been appointed Executive Vice President, Services & Manufactured Products, a newly created role, effective August 2, 2023. In his new role, Pearson will gain responsibility for PetIQ's manufactured product portfolio, inclusive of the Company's sales and marketing teams, while maintaining his current responsibilities for the Services segment. Pearson will continue to report directly to Michael Smith, President and Chief Ope
#1 Cookie, Cracker, and Baking Mix Brand in the Natural Channel Taps Industry Veteran to Provide Guidance in Innovation and Sustainability Simple Mills, the company on a mission to advance the holistic health of the planet and its people through delicious, better-for-you foods, today announced the addition of CPG industry veteran, Sheryl O'Loughlin, to its Board of Directors. O'Loughlin is an accomplished entrepreneur, CEO, author, and board member bringing extensive experience leading fast-growing, innovative consumer products companies. In her new role, O'Loughlin will provide strategic counsel and guidance to help support Simple Mills in scaling the company to the next level, creating o
EAGLE, Idaho, May 18, 2022 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced the appointment of accomplished retail operations executive, John Pearson, to Senior Vice President, Head of Services Division, reporting to Michael Smith, President and Chief Operating Officer, effective today. Pearson will be responsible for managing all aspects of PetIQ's Services Division, including strategy and operations to fuel future growth in revenue and profitability. Cord Christensen, Chairman and CEO commented, "On behalf of the Board of Directors and management team, I'd like to welcome John to the PetIQ family. Jo
EAGLE, Idaho, Jan. 06, 2022 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced the appointment of Kenneth Walker as an independent director on its Board of Directors, effective January 3, 2022. He will also serve on the Audit Committee of the Board. Walker has 24 years of financial experience supporting consumer, retail and e-commerce companies. "On behalf of our Board of Directors and management team, I am very pleased to welcome Kenneth to our team as an independent director," Cord Christensen, Chairman and CEO of PetIQ, commented. "His tremendous depth of financial expertise particularly across indust
EAGLE, Idaho, Jan. 05, 2022 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced the appointment of Zvi Glasman, as its Chief Financial Officer ("CFO"), effective January 3, 2022. Glasman has 20 years of CFO experience supporting high growth companies to drive operational improvements and increased profitability. "I am excited to welcome Zvi to PetIQ. He is a strong public company CFO with a track record of success across consumer, manufacturing, and software companies, which will help him make an immediate impact at PetIQ," commented Cord Christensen, PetIQ's Chairman & CEO. "Zvi joins PetIQ at an ideal t
EAGLE, Idaho, Feb. 24, 2021 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced the appointments of Sheryl Oloughlin and Kim Lefko as independent directors on its Board of Directors, effective March 2, 2021. These additions of Ms. Oloughlin and Ms. Lefko fill vacancies on the Company’s Board of Directors and will increase the size of the Board from five to seven. Ms. Oloughlin will join the Board as Class I director and as a member of the Company’s Compensation Committee, with a term expiring at the Company’s annual meeting of stockholders in 2021. Ms. Lefko will join the Board as a Class III director an
https://x.com/TheRoaringKitty/status/1806371920495186041
Benchmark analyst John Lawrence reiterates PetIQ (NASDAQ:PETQ) with a Buy and maintains $30 price target.
For the second quarter of 2024 the Company expects: Adjusted EBITDA of $34.0 million to $36.0 million. For the full year 2024 the Company expects: Adjusted EBITDA of $112.0 million to $118.0 million.
PetIQ (NASDAQ:PETQ) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.43 by 34.88 percent. This is a 28.89 percent increase over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $308.443 million which beat the analyst consensus estimate of $300.493 million by 2.65 percent. This is a 6.19 percent increase over sales of $290.471 million the same period last year.
Jefferies analyst Kaumil Gajrawala maintains PetIQ (NASDAQ:PETQ) with a Buy and raises the price target from $24 to $28.
For the full year 2024 the Company expects Adjusted EBITDA of $109.0 million to $114.0 million. For the first quarter of 2024 the Company expects Adjusted EBITDA of $31.0 million to $33.0 million
PetIQ (NASDAQ:PETQ) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings PetIQ beat estimated earnings by 59.0%, reporting an EPS of $-0.12 versus an estimate of $-0.29. Revenue was up $35.85 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.4 which was followed by a 3.0% drop in the share price the next day. Here's a look at PetIQ's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate 0.02 0.26 0.35 -0.09 EPS Actual 0.42 0.46 0.45 -0.10 Revenue Estimate 229.06M 273.76M 277.23M 192.47M Revenue Actual 277.02M 314
PetIQ (NASDAQ:PETQ) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.29) by 58.62 percent. This is a 20 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $219.93 million which beat the analyst consensus estimate of $189.05 million by 16.33 percent. This is a 19.47 percent increase over sales of $184.08 million the same period last year.
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.27 per share on revenue of $193.12 million. • Wallbox (NYSE:WBX) is likely to report earnings for its fourth quarter. • Immunocore Hldgs (NASDAQ:IMCR) is estimated to report quarterly loss at $0.28 per share on revenue of $67.23 million. • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.08 per share on revenue of $9.95 billion. • TG Therapeutics (NASDAQ:TGTX) is likely to report quarterly loss at $0.10 per share on revenue of $40.06 mil